Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40620-022-01367-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Carfilzomib-related glomerular and tubular injury in a patient with Multiple Myeloma.
J Nephrol
November 2022
Department of Clinical and Experimental Medicine, Hematology Unit, University of Pisa, Pisa, Italy.
Cardiac and renal complications of carfilzomib in patients with multiple myeloma.
Blood Adv
February 2017
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Clinical trials with carfilzomib have indicated a low but reproducible incidence of cardiovascular and renal toxicities. Among 60 consecutive myeloma patients treated with carfilzomib-based regimens who were thoroughly evaluated for cardiovascular risk factors, 12% (95% confidence interval, 3.8%-20%) experienced a reversible reduction of left ventricular ejection fraction (LVEF) by ≥20%, an objective measure of cardiac dysfunction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!